Compare Cytokinetics Inc (CYTK) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Cytokinetics Inc trades at $62.73 (market cap $8.62B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.11 (market cap $17.89B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is far larger — about 2.1× Cytokinetics Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days on average.
| CYTK | HYG | |
|---|---|---|
Market Cap | $8.62B | $17.89B |
Volume | 2,594,626 | 44,866,592 |
Sector | Health | Fixed Income |
52-Week High | $87.26 | $81.28 |
52-Week Low | $54.76 | $76.90 |
Typical Hold Time | 19 Days | 59 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
HYG (iShares iBoxx $ High Yield Corporate Bond ETF) trades at $77.115, down 0.08% with a bearish technical signal from moving averages. The fund has shown unusual options activity recently amid a challenging bond market environment where Treasury yields have reached multi-year highs. Recent dividend payments of $0.34-$0.44 per share provide income support, but the overall technical picture remains weak with significant selling pressure.
The outlook for HYG remains challenged by rising interest rates and bond market volatility. While the fund offers attractive yield income through regular dividends, the bearish technical momentum and elevated Treasury yields create headwinds for price appreciation. Key risks include further rate hikes and credit spread widening in the high-yield bond market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
